Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696376 | 0.98 | L3MBTL1 (0.42) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL697748 | 0.94 | L3MBTL1 (0.42) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL697320 | 0.90 | — | — | |
| SCHEMBL17223944 | 0.81 | HPGD (0.41) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL1439007 | 0.81 | ALDH1A1 (0.39) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL1996672 | 0.80 | EPHX1 (0.41) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL1439288 | 0.79 | L3MBTL1 (0.39) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL1438974 | 0.78 | L3MBTL1 (0.40) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL607588 | 0.78 | L3MBTL1 (0.39) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL1439754 | 0.77 | L3MBTL1 (0.40) | EPHX1HPGDKMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498159-B1 | SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE | EISAI CO., LTD. (JP) | 2002-12-24 | — | — | US | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| EP-0643059-A1 | 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors | Pfizer Limited (GB) | 1995-03-15 | — | — | EP | claimed |
| EP-0295100-B1 | Methoxymethyl compounds | ERBA CARLO SPA (IT) | 1994-09-14 | — | — | EP | claimed |
| EP-0594588-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1994-05-04 | — | — | EP | claimed |
| EP-0358398-B1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1993-03-10 | — | — | EP | claimed |
| WO-1992014706-A1 | CYCLOPENTANE-DERIVED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1992-09-03 | — | — | WO | claimed |
| US-5081116-A | A 7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido, 3-(1,3-dithiolan-2-yl)-3-cephem-4-carboxylic acid and ester derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-01-14 | — | — | US | claimed |
| WO-1991013054-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1991-09-05 | — | — | WO | claimed |
| EP-0392796-A2 | Cephalosporin derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-10-17 | — | — | EP | claimed |
| US-4952577-A | ANTIBIOTICS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-08-28 | — | — | US | claimed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | claimed |
| US-4874856-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1989-10-17 | — | — | US | claimed |
| EP-0304036-A2 | 3-(substituted)propenyl-7-(aminothiazolylacetamido)ceph-3-em-4-carboxylic acids and esters thereof | Bristol-Myers Squibb Company (US) | 1989-02-22 | — | — | EP | claimed |
| EP-0295100-A1 | Methoxymethyl compounds | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-12-14 | — | — | EP | claimed |
| JP-3047187-A | — | — | None | — | — | JP | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-0304036-A2 | 3-(substituted)propenyl-7-(aminothiazolylacetamido)ceph-3-em-4-carboxylic acids and esters thereof | Bristol-Myers Squibb Company (US) | 1989-02-22 | — | — | EP | disclosed |
| EP-0304036-A2 | 3-(substituted)propenyl-7-(aminothiazolylacetamido)ceph-3-em-4-carboxylic acids and esters thereof | Bristol-Myers Squibb Company (US) | 1989-02-22 | — | — | EP | disclosed |
| US-4731361-A | Alkeneamidocephalosporin esters | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | EPHX1 490/4885HPGD 22/4885KMT2A 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.